Welcome to our dedicated page for Halozyme Thrp SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Halozyme’s royalty-rich disclosures can feel like searching for a single amino acid in a protein chain. The company’s 300-page reports weave ENHANZE licensing revenue, clinical trial spend, and complex milestone accounting into dense tables that few investors have time to unravel. If you have ever typed “Halozyme insider trading Form 4 transactions” or “Halozyme quarterly earnings report 10-Q filing” into a search bar, you already know the challenge.
Stock Titan solves the problem in minutes, not days. Our AI reads every 10-K, 10-Q, 8-K and S-3 the instant it hits EDGAR, then delivers plain-English answers to common questions such as “Halozyme SEC filings explained simply” and “understanding Halozyme SEC documents with AI.” Need to monitor material events? “Halozyme 8-K material events explained” appears with context minutes after filing. Want alerts on executive activity? “Halozyme Form 4 insider transactions real-time” and “Halozyme executive stock transactions Form 4” land in your dashboard before the market can react.
Each document is paired with concise AI summaries that spotlight: royalty percentages from Roche or Pfizer collaborations, pipeline milestone triggers, and cash-flow impacts of inventory builds. Use cases include:
- Comparing R&D burn across quarters with our “Halozyme earnings report filing analysis.”
- Reviewing compensation tables via “Halozyme proxy statement executive compensation.”
- Scanning the “Halozyme annual report 10-K simplified” section for segment revenue trends.
Whether you are modeling future royalties or timing trades around clinical catalysts, our real-time updates and expert insights transform raw HALO disclosures into decision-ready intelligence—no PhD in biochemistry required.
Halozyme Therapeutics (HALO) President and CEO Helen Torley executed a series of pre-planned transactions under a Rule 10b5-1 trading plan established on March 21, 2025. The transactions occurred over three consecutive days:
- June 20, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares at avg. $52.96
- June 23, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares at avg. $52.57
- June 24, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares (4,489 at avg. $53.11 and 15,511 at avg. $53.91)
Following these transactions, Torley holds 733,719 shares directly and 316,569 options at $8.11 strike price expiring February 3, 2026. The options were originally granted in 2016 with a 4-year vesting schedule. All transactions were executed under a pre-established 10b5-1 trading plan, demonstrating compliance with insider trading regulations.
Citigroup Global Markets Holdings Inc. (guaranteed by Citigroup Inc.) is issuing Medium-Term Senior Notes in the form of Autocallable Contingent Coupon Equity-Linked Securities linked to Tesla, Inc. The notes are offered at $1,000 par, mature on 29 June 2028 and have an aggregate face amount of $1.186 million.
Income potential: Quarterly contingent coupons of 1.1125 % (13.35 % p.a.) are paid only when Tesla’s closing price on each valuation date is ≥ the coupon barrier of 50 % of the initial level ($163.775). Missed coupons “accrue” and are payable if the barrier is later satisfied.
Autocall feature: Beginning 26 Dec 2025, the notes are automatically redeemed at $1,000 + coupon if Tesla closes ≥ its initial level ($327.55) on any of 30 scheduled valuation dates, cutting off future coupons.
Principal repayment: • If not called and Tesla’s final price is ≥ the final barrier (50 % of initial), holders receive par. • If it is below the barrier, investors receive $1,000 × (1 + return), fully exposing them to downside, with a potential loss of the entire investment and forfeiture of unpaid coupons.
Pricing & fees: Issue price $1,000; estimated value $948.10 (≈5.2 % discount). Underwriting fee is 4.5 % ($45 per note), with proceeds of $955 to the issuer. Notes are unsecured, unsubordinated and not listed; liquidity will rely on the underwriter’s informal market.
Key risks include Tesla share volatility, early redemption limiting upside, barrier breach leading to principal loss, liquidity constraints and the credit risk of both Citigroup Global Markets Holdings Inc. and Citigroup Inc.
FAQ
What is the current stock price of Halozyme Thrp (HALO)?
What is the market cap of Halozyme Thrp (HALO)?
What is Halozyme Therapeutics' core business?
How does the ENHANZE technology work?
What therapeutic areas does Halozyme target?
How does Halozyme generate revenue?
Who are some of Halozyme's key partners?
What differentiates Halozyme from other biotech companies?
How does Halozyme contribute to improved patient outcomes?
What is the significance of Halozyme's strategic partnerships?
